Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
688687.SS
SELLREMOVEBeijing Kawin Technology Share-Holding Co., Ltd. · Healthcare · China · $431M · Avg Vol: $6M/d
Beijing Kawin is a small biotech firm that lacks internal manufacturing scale, leaving it highly vulnerable to rising manufacturing costs from dominant CDMOs.
COMPANY DESCRIPTION
Beijing Kawin Technology Share-Holding Co., Ltd. is a biopharmaceutical company specializing in the prevention and treatment of viral infections, with a focus on chronic hepatitis B and C. The company's competitive moat is anchored by its proprietary recombinant human interferon products and a robust pipeline of innovative biologics. It holds a leading position in China's antiviral therapeutic market.
FINANCIAL SUMMARY
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 171M | 209M | 182M | 195M | 4.4% |
| EPS | 0.07 | 0.10 | 0.13 | 0.03 | -28.4% |
| Shares | 171M | 171M | 171M | 171M | +0.0% |
| Debt | 2M | 8M | 37M | 75M | 218.4% |
| Equity | 248M | 259M | 272M | 252M | 0.6% |
| Op CF | 20M | 19M | 15M | 16M | -6.3% |
| Inv CF | -73M | -9M | -26M | -47M | — |
| Fin CF | -11M | 1M | 12M | 16M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688687.SS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 688687.SS | Beijing Kawin Technology Share-Holding Co., Ltd.(you) | $431M | 24 | SELL |
| 603896.SS | Zhejiang Shouxiangu Pharmaceutical Co., Ltd. | $452M | 27 | SELL |
| 6660.HK | AIM Vaccine Co., Ltd. | $368M | 20 | SELL |
| 688075.SS | Assure Tech (Hangzhou) Co., Ltd. | $643M | 27 | SELL |
| 2197.HK | Clover Biopharmaceuticals, Ltd. | $323M | 19 | STRONG SELL |
| 6996.HK | Antengene Corporation Limited | $347M | 15 | STRONG SELL |
| 1167.HK | Jacobio Pharmaceuticals Group Co., Ltd. | $490M | 12 | STRONG SELL |
| 688302.SS | Hinova Pharmaceuticals Inc. | $582M | 14 | STRONG SELL |
| 6955.HK | Shandong Boan Biotechnology Co., Ltd. | $455M | 9 | STRONG SELL |
| 688197.SS | Shouyao Holdings (Beijing) Co., LTD. | $804M | 19 | STRONG SELL |
Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.0%